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Abstract
Hypothalamic hamartomas (HH) are rare, basilar developmental lesions with widespread
comorbidities often associated with refractory epilepsy and encephalopathy. Imaging advances
allow for early, even prenatal, detection. Genetic studies suggest mutations in GLI3 and other
patterning genes are involved in HH pathogenesis. About 50%–80% of children with HH have
severe rage and aggression and a majority of patients exhibit externalizing disorders. Behavioral
disruption and intellectual disability may predate epilepsy. Neuropsychological, sleep, and
endocrine disorders are typical. The purpose of this article is to provide a summary of the
current understanding of HH and to highlight opportunities for future research.
Introduction
Hypothalamic hamartomas (HHs) are deep-seated developmental lesions that have varied manifes-
tations. This review is based on the 4th International Symposium on Hypothalamic Hamartomas,
which took place September 12–14, 2019, in Washington, DC, and current concepts, experience, and
research. The reader is provided a key clinical summary of HH as well as the most current recom-
mendations for workup and diagnosis. We summarize current thinking regarding pathophysiology,
genetic underpinnings, and broad comorbidities of the disease. The surgical management of HH is
reviewed. Finally, future research and clinical priorities are considered.
Search Method
We conducted a thorough search of the literature through PubMed with the search phrase
“hypothalamic hamartoma,” identifying 770 articles, 111 of which were published from 2018 to
2021, which were reviewed for content. The subsection editors also reviewed references in their
respective sections in regard to their command of material and PubMed.We have included in our
references the major publications from the past 3 years and major publications prior to 2018.
Where relevant, we listed the most recent article or review (especially for the surgical literature)
and we recognize this is often at the expense of the original work or observation. Those important
references will be found in the articles’ citations.
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Clinical Summary
HHs are lesions of varying size that arise in the ventral
hypothalamic region. They are commonly associated with
diverse neurologic, endocrinologic, cognitive, behavioral,
and psychiatric comorbidities, including epilepsy, epileptic
encephalopathy, precocious puberty, and rage. There are 2
classic clinical phenotypes of HH, intrahypothalamic and
parahypothalamic, and each is associated with a typical
clinical spectrum. Intrahypothalamic HH is associated with
epilepsy with gelastic and other seizure types and is often
pharmacoresistant. The HH syndrome may include the
evolution of developmental regression, psychiatric and
behavioral comorbidities, and precocious puberty.1 Para-
hypothalamic HH is usually only associated with endo-
crinopathy, such as precocious puberty. Epilepsy and
cognitive and behavioral disturbances can occur, although
rare.2
The prevalence of HH is estimated to be 1 in 200,000 chil-
dren.3 The epilepsy syndrome is often associated with the
occurrence of gelastic seizures, which are episodes of un-
controllable mirthless laughter, often unrecognized in the
early years. These can evolve to include focal seizures with
impaired awareness, dacrystic (crying), atypical absence,
tonic, atonic, and generalized tonic-clonic seizures, as well as
infantile spasms.4,e1,e2,e3 Age at onset is typically less than a
year for gelastic seizures and between 2 and 7 years of age for
additional focal seizure types, both of which are often re-
fractory to medical treatment. Due to the variable clinical
presentation, the actual prevalence of pharmacoresistant ep-
ilepsy in HH is unknown5 but has been reported in various
series between 50% and 100%; this high prevalence may
represent selection and referral bias.6,e4 Rarely, the disorder
can be mild and escape diagnosis with symptoms such as “a
pressure to laugh” in association with normal cognitive and
social development.7
The diagnostic evaluation of HH remains challenging. Due to the
depth of the lesion, scalp EEG may be falsely normal without
evidence of interictal abnormality; ictal surface EEG can be dif-
ficult to localize or may be misleading.8 In one study of 133
patients with HH, 75% of 584 captured gelastic seizures (56% of
patients) had no ictal EEG change.9 The hamartoma can be
difficult to identify on imaging due to its small size and location,
even by experienced neuroradiologists. A high-resolution 3T
brain MRI with epilepsy-specific protocol including thin cut 3D
T1-weighted (≤1mm3 voxel), T2-weighted, and fluid-attenuated
inversion recovery sequences (minimum2planes, 3D better) will
reliably identify HHs.10,e5 The 2014 Florence consensus of the
Pediatric Epilepsy Surgery Task Force of the International Lea-
gue Against Epilepsy recommends ictal/interictal EEG to con-
firm diagnosis (not for localization) as well as 3D volumetric
MRI; PET and SPECT are not recommended given significant
false results.11 The interpretation of this imaging often requires
specific expertise, usuallymore readily available at skilled pediatric
epilepsy surgery centers. HH is associated with a varying
comorbidity profile that includes neurodevelopmental, behav-
ioral, and psychiatric disorders. Psychiatric comorbidities occur in
more than 50% of children.12,e6 Rage attacks, as well as less severe
aggressive behaviors and attentional problems, are common.6,13
Cognitive impairments have been reported in more than 80% of
patients, and these appear to be progressive in half of cases. In
view of the apparent relationship between the epilepsy onset and
neurocognitive difficulty, the syndrome is considered an epileptic
encephalopathy, with increased seizure burden contributing to
worse cognitive outcomes.Hamartoma removal or disconnection
is qualitatively linked to improved cognitive and behavioral out-
comes14; single-center studies show quantitative improvements
in full-scale IQ in patients undergoing pre- and postoperative
neuropsychological testing.15
There are several hypotheses about how the encephalopathy
may develop. It may represent an ictal, interictal, or combined
phenomenon.16 The encephalopathy may be mediated by the
disruption of structural and functional hypothalamic projec-
tions including tegmental, mammillo-thalamo-cingulate, and
more distributed networks.4,e7 There may be local effects
within the hypothalamus and depending on which subnuclei
are involved, with resultant endocrinologic or functional dis-
turbances contributing to the encephalopathy, as is known to
occur in brain tumor diencephalic syndromes. This has also
been shown in PET studies in HH.e8
Pathophysiology and Imaging
The cell of origin of HH and the cause of gelastic seizures
remains unknown. HHs develop in a region rostral to the
mammillary body. A cell group in this region called the lateral
tuberal nucleus (LTN) is hypothesized to be the origin of
HH. Neurofibrillary tangles are often found in HHe9 by his-
topathology and also in the LTN in neurodegenerative dis-
orders such as Alzheimer disease. A similar cell group
(parvalbumin-containing cells) called PV1 lies in a homolo-
gous rodent region and has strong connections to the
Glossary
ADHD = attention-deficit/hyperactivity disorder;GKS = Gamma Knife radiosurgery;HH = hypothalamic hamartoma;HOS =
hypothalamic obesity syndrome; LGG = low-grade glioma; LITT = laser interstitial thermal therapy; LTN = lateral tuberal
nucleus; PHS = Pallister-Hall syndrome; SRT = stereotactic radiofrequency thermocoagulation; SUDEP = unexplained death
in epilepsy.
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ventrolateral periaqueductal gray.17 PV1 cells are associated
with generating species-specific vocalizations such as cackling
in monkeys. The overgrowth of LTN-derived neurons (HH)
could disinhibit PV1 neurons from their normal anterior hy-
pothalamic inputs and may cause the laughter associated with
gelastic seizures.18 Due to the deep-seated location of the
hypothalamus and the recent frequent use of minimally in-
vasive treatment such as laser ablation, there is a paucity of
available tissue for study. Newer techniques may allow for
tissue recovery from probes used in ablation, as has recently
been demonstrated for surgically implanted stereotactic EEG
depth electrodes.e10
Imaging allows for early detection of HH with high-
resolution fetal MRI. The lumen of the third ventricle is not
fully established until 26–28 weeks gestational age, so it is
difficult to diagnose HH until the second trimester. A
common misdiagnosis at this time are interhypothalamic
adhesions, which are horizontally oriented bands that
connect the medial walls of the third ventricle.19 HH are
nonenhancing, may be relatively isodense, and may range in
size from 2 to 20 mm.20
Genetics
Advances have been made in the genetic underpinnings of
HH. The Sonic hedgehog (Shh) pathway regulates neu-
rogenesis and cell patterning in early hypothalamic de-
velopment; mutations in this pathway can cause increased
proliferation of nearby wild-type cells.21 Using whole-
exome sequencing, chromosomal microarray, and targeted
candidate gene sequencing, somatic mutations of Shh
pathway-related genes are discovered in one third of tissue
and cell samples of patients with nonsyndromic HH.22
Similarly, germline mutations in GLI3, a transcriptional
activator and repressor of downstream Shh pathway tar-
gets, cause Pallister-Hall syndrome (PHS), a form of syn-
dromic HH, which can be associated with polydactyly or
syndactyly, bifid epiglottis, imperforate anus, and renal
abnormalities.23,e11 Patients with PHS have less severe
epilepsy and fewer neuropsychiatric problems than those
with isolated HH.24
The location of variants in the GLI3 gene is associated with
different clinical manifestations: frameshift mutations in
the middle third of the gene cause PHS, whereas those in
the first or last third of the gene cause a distinct syndrome
called Greig cephalopolysyndactyly syndrome (poly- or
syndactyly, hypertelorism, macrocephaly), which is not
associated with HH. The mechanism of this variable pre-
sentation was demonstrated in Drosophila, which have a
homologous gene pathway to human GLI3. The location of
a frameshift mutation in GLI3 can direct whether the
downstream function of the resultant protein is activating
or repressing, and thus how a single gene mutation can lead
to various phenotypes.25
An emerging concept is that HH may also develop from
biallelic germline and somatic variants within cilia, in-
cluding Shh pathway genes. The cellular signaling function
of Shh proteins depends on their trafficking by cilia during
development.26 There is preliminary evidence for this in
several cilia genes through genetic analysis of a Japanese
HH cohort,27 and the recent discovery of a biallelic variant
in the cilia and hedgehog gene SMO in 7 patients with
broad developmental anomalies including HH.28 Demon-
stration of this mechanism in further cilia genes of addi-
tional nonsyndromic cases would confirm that HH is a
ciliopathy. This mechanism may allow for direct thera-
peutic targeting.
Focus on Comorbidities
Psychiatric
HH is often complicated by psychiatric disorders, which may
occur in up to 60%–80% of pediatric cases.12 Rage attacks are a
poorly defined yet fundamental element of the psychiatric profile
associated with the disease.e12 In a cohort of 46 children with
hypothalamic hamartoma, almost half demonstrated rage at-
tacks.12 These events are thought to be caused by biological
difficulties with emotional regulation combined with increased
aggressive tendencies; their relationship to epilepsy is unclear.
Rage attacks and autism spectrum disorder were over-
represented in the Hope for HH International Comorbidity
Survey of more than 250 international patients and families
(Soeby and Webster, unpublished data; see below). Aggressive
behavior more commonly occurs in male patients, those with
intellectual disability, those with younger age at seizure onset,
and patients with multiple seizure types.29 Other commonly
encountered psychiatric comorbidities include oppositional de-
fiant disorder, attention-deficit/hyperactivity disorder (ADHD),
as well as anxiety and mood disorders.30 The rates of ADHD,
anxiety disorders, andmood disorders are similar to those seen in
many other childhood onset epilepsies; similarly high rates of
depression and anxiety exist in adult patients with HH.31,32
There is no clear relationship to Delalande subtype.
Neurodevelopmental
Children with HH exhibit a variety of cognitive profiles from
normal to severe disability. Cognitive dysfunction may be
progressive and appears dependent on a number of factors.
Neurodevelopmental disability is more common in patients
with HH with epilepsy. Studies find more severe cognitive
impairment in patients with earlier onset of epilepsy, increased
seizure burden, increased number of antiseizure medications,
and, for some, larger lesion burden.29,33,e13-e16 In a retrospective
study of 48 patients with HH-associated epilepsy, half of the
patients exhibited executive and 62% had verbal memory
dysfunction preoperatively. The majority of patients in this
study achieved postoperative improvements in intellectual
functioning after interstitial radiosurgery or transcallosal/
endoscopic resection.34 A study of 88 patients with HH un-
dergoing stereotactic radiofrequency thermocoagulation sur-
gery showed postoperative neuropsychological improved
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performance in all patients (even in those without significant
preoperative neurocognitive dysfunction).35 However, the re-
lationship between seizures and cognition is unclear as there are
cases where successful surgery with regard to seizure control
may not normalize other comorbidities/encephalopathy. Early
surgery is thought to minimize the risk of encephalopathy, but
this remains untested. Many children with HH have de-
velopmental and cognitive impairments that predate the rec-
ognition of development ofHH-associated epilepsy, whichmay
indicate these effects are mediated by HH interference of
normal behavioral and memory circuitry. These issues are
further compounded by the development of intractable epi-
lepsy, which adds to the burden of disease.12
Sleep
Patients with HH have refractory epilepsy, which can in-
terrupt sleep, leading to an overall poor sleep quality. A cohort
of 41 patients with HH from Freiburg, Germany, had less
slow-wave sleep than healthy controls. Increased epileptic
spikes during sleep are associated with lower IQ and increased
nocturnal seizure burden worsens neuropsychological per-
formance (Jacobs, unpublished data). Slow wave sleep has
been demonstrated to be important for memory consolida-
tion in children with other focal epilepsies.36 As there are no
published reports on the relationship of HH and sleep, the
mechanisms underlying sleep disturbance and cognitive dys-
function remain to be elucidated.
Endocrine
The typical primary preoperative endocrinopathy associated
withHH is central precocious puberty,37 probably because of the
premature pulsatile release of hypothalamic gonadotropin-
releasing hormone.6,37 Occasionally, hypogonadism or acro-
megaly can be seen,e17 and there is a case report of a HH
secreting corticotrophin-releasing hormone, causing elevated
serum cortisol levels.e18 Most of the other endocrine disorders
are less common and occur after treatment (e.g., postsurgical or
radiation-induced),38 but require surveillance and follow-up. The
endocrine manifestations include diabetes insipidus,38 growth
hormone deficiency,e19 central hypothyroidism,38,39 and the
hypothalamic obesity syndrome (HOS).38,39 The diagnostic
workup and treatment of these endocrinopathies are in accor-
dance with clinical practice guidelines set forth for diabetes
insipiduse20 and hypopituitarisme21 for patients without HH.
Approximately 20% of patients with HHdevelop the difficult-to-
treat HOS (hyperphagia, weight gain). HOS management
strategies are based on current childhood obesity guidelines in-
cluding diet and exercise, drug interventions with octreotide,40
metformin, potentially newer obesity drugs, and bariatric sur-
gery.41 The etiology of HOS is difficult to identify as there can be
premorbid obesity in up to half of patients with HH prior to
surgery. A semi-quantitative MRI-based scoring system of
damage to hypothalamic regions can help predict, based on
postoperative imaging, which patients are at risk of developing
HOS after surgery.42 Postoperative hypothalamic injury is cor-
related with HOS after damage to posterior hypothalamic sub-
nuclei (such as the dorsomedial nucleus and the dorsal
hypothalamic area). These areas are involved in promotion of
energy expenditure: contributions from the dorsomedial nucleus
cause release of thyrotropin-releasing hormone from para-
ventricular nucleus neurons; the dorsal hypothalamic area is
involved in thermoregulation, activation of brown fat, and
locomotion.42
Quality of Life and SUDEP
Hope for HH undertook an international survey of families
including 256 respondents (mean age, 18 years; range, 1–55
years) from more than 20 countries to provide information to
inform new areas for research and clinical interventions. In
this survey, top family concerns are seizures, cognitive se-
quelae, future uncertainty, psychiatric and behavioral prob-
lems, inability to lead an independent life, safety, and sudden
unexplained death in epilepsy (SUDEP). Of 256 respondents,
162 had one or more surgical or radiation treatments: laser
Table 1 Surgical Techniques for HH
Endoscopic (n = 136) GKS (n = 135) SRT (n = 210) LITT (n = 101) FUS (n = 3)
Outcomes Engel I + II; 77% Engel I + II; 57% Engel I; 88% Engel I; 93% Engel I; 66%
Complications Overall 8.4%
• Memory deficit 2.8%
• Oculomotor palsy 0.9%
• Motor with partial
recovery 2.35%
• Weight gain 2.35%
• Transient ↑ seizure 16.6%
• Transient temperature
instability 6.2%
None reported • Endocrine (most common
thyroid) 11%
• Memory 2%
None reported
Who does well? ↓ Duration epilepsy HH Class I, II, or III ↓ Duration epilepsy Smaller lesions N too small
Special
considerations
• Worse if preexisting
cognitive deficit
• ↑ Complications w/larger
HH
• Not for large HH
• Delayed effect (up to 2
years)
•Works for all HH sizes/types
• Good outcomes for
nongelastic epilepsy
• Larger HH ≥ salt wasting
• 23% need 2nd ablation
Further studies
needed
Abbreviations: FUS = focused ultrasound; GKS = Gamma Knife surgery; HH = hypothalamic hamartoma; LITT = laser interstitial thermal therapy; SRT =
stereotactic radiofrequency thermocoagulation.
Less commonly employed microsurgical techniques are discussed in the section on surgical techniques. FUS is an emerging technology and was included in
this chart for the purposes of comparison. References are in the Surgical and Therapeutic Techniques section.
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ablation (n = 61), endoscopic resection (n = 31), transcallosal
resection (n = 30), Gamma Knife (n = 27), radiofrequency
ablation (n = 27), orbitozygomatic resection (n = 9), and
other (n = 27). About half of children achieved seizure free-
dom. The majority of caregivers reported sleep disturbances,
including excessive daytime fatigue and sleep disruption.
Endocrine problems were common: >40% report precocious
puberty, with many others experiencing abnormal tempera-
ture regulation (40%), hypothyroidism (20%), and other
signs/symptoms of hypothalamic-pituitary-adrenal axis dys-
function. Emotional dysregulation is frequent, and a majority
of patients register rage attacks or behavioral outbursts. More
than 40% of patients received a formal diagnosis of an anxiety
disorder. A majority of patients have cognitive issues, in-
cluding >60% of respondents reporting memory problems,
learning disabilities, and developmental delays. In 2019, 3
children from the Hope for HH community died of SUDEP,
raising the concern that patients with HH are at an increased
risk for SUDEP.
Surgical and Therapeutic Techniques
Several surgical approaches are used to treat HH-mediated
epilepsy depending on the location and size of HH, local
expertise, and technology available. Surgical procedures
can be classified according to their rationale (resection vs
disconnection; image-based vs functional) or type of ap-
proach (open vs minimally invasive). Table 1 summarizes
the main surgical and therapeutic techniques currently
being used to treat HH. Except for radiofrequency stereo-
tactic disconnection, all other procedures available for
treatment of HH require some type of HH resection. An
image-based approach is preferred although some series
showed that neurophysiologic data may affect outcome,
which is awaiting validation. Endoscopic and stereotactic
approaches are considered less invasive than open proce-
dures. Endoscopic approaches might be considered more
invasive compared to stereotactic, although no head-to-
head comparison is available. Morbidity is related to
number of trajectories during stereotactic procedures. One
advantage to open and endoscopic procedures is that they
can provide tissue specimens. It is arguable that lack of
tissue sampling in laser interstitial thermal therapy (LITT),
radiofrequency, focused ultrasound, or radiosurgery
procedures might negatively affect patient care, outcome,
and research in the future, although it may be possible to
recover DNA from cells recovered from HH probes. For
example, there are para- and intrahypothalamic hamarto-
mas, which have different associated morbidities. A recent
review summarizes the most updated neurosurgical data.43
The Delalande classification system groups HH into 4 types
based on location and is in turn related to surgical trajectory/
approaches and surgical morbidities (Figures 1 and 2).44
Endoscopic resection/disconnection can be performed by
means of bipolar, radiofrequency, or laser coagulation and
achieves a high level of seizure control (up to 78% Engel I +
II) but can have an overall complication rate up to 8.3% in a
series of 112 patients.39,e22,e23 The most common adverse
outcomes were transient short term memory deficit (n = 5),
oculomotor nerve palsy (transient n = 9, ongoing n = 3),
hemiplegia (n = 4), and infection (n = 4). e18 Gamma Knife
radiosurgery (GKS) has good long-term safety/efficacy data,
but requires a substantial time (up to 2 years) before positive
effects are seen, and is not recommended for larger HH.45,e24
In a prospective trial of 48 patients with GKS, 68.8% were
Engel I + II at last follow-up; no endocrinologic, motor, or
amnestic complications were reported.45 Stereotactic radi-
ofrequency thermocoagulation (SRT) can be applied to
every type/size of HH with significant reduction of gelastic
seizure burden.35,e25,e26 In a study of 100 patients with HH,
SRT led to Engel I outcome in 71% from all seizures types
with improved IQ 1 year postprocedure in 69% of the co-
hort, and reported resolution of behavioral problems in the
entire cohort; complications include weight gain, post-
procedure precocious puberty, and pituitary dysfunction.15
LITT achieves 93% seizure freedom at 12 months46; how-
ever, it can be associated with salt wasting with treatment of
larger HH.47,e27,e28 In a series of 18 patients undergoing
LITT, complications included weight gain (22%), short term
memory loss (22%), and delayed hypothyroidism (11%).48
The (surface) laser probe used in endoscopic procedures
(distinct from that used during laser interstitial thermal
therapy) is applied under direct visualization without intra-
operative imaging feedback.49 MRI-guided focused ultra-
sound thermoablation is a newer noninvasive method being
studied. There are also open microsurgical techniques
Figure 1 Delalande Classification of Hypothalamic Hamartomas
Type I lesions have horizontal attachment inferior
to floor of the third ventricle. Type II lesions have
vertical attachment to the wall of third ventricle
and are above the floor of the third ventricle.
Type III lesions have horizontal and vertical at-
tachments above and below the floor of the third
ventricle. Type IV lesions are considered “giant”
with volume 8 cm3 or larger (used with permis-
sion from Barrow Neurologic Institute, Phoenix,
AZ).
868 Neurology | Volume 97, Number 18 | November 2, 2021 Neurology.org/N
including transcallosal resection, orbitozygomatic ap-
proach,50 transventricular, transcortical, and pterional
approaches for the surgical treatment of HH; the orbito-
zygomatic and pterional approaches may have higher risk
than other approaches. There has been a trend away from
open microsurgical techniques (such as the original Aus-
tralian transcallosal approach) to more minimally invasive
techniques such as laser interstitial thermal therapy, SRT,
and focused ultrasound as success is high and surgical
morbidity reduced. In a cohort of 26 patients with HH
treated with transcallosal resection, 88% of patients had
behavioral improvement; 58% had transient postoperative
memory dysfunction and 65% had overall improvement.38
A smaller study of 10 patients treated with orbitozygo-
matic resection, not suitable for lesions below the IIIrd
ventricular floor, had 80% improvement in overall quality
of life, and 33% of patients experienced improvements in
presurgical behavioral and mood problems.50 It is postu-
lated that many of the presurgical memory problems relate
to HH and proximity to the mammillary bodies; increased
anterior–posterior extension around the mammillary
bodies is associated with increased risk of cognitive
problems.51 Surgical techniques, such as endoscopic or
microsurgical transcallosal approaches, can incur forniceal
contusion, which is related to postoperative memory
dysfunction.52
A cross-sectional comparative surgical effectiveness feasibility
study from 14 international centers of 94 patients (mean 11.8
years, range 1 to 69 years of age) was performed in 2019 on
children who underwent epilepsy surgery in 2014–2015. This
study did not identify a clear distinction among surgical ap-
proaches but demonstrates the need for larger studies and
provided evidence of feasibility to that goal (Hesdorffer et al.,
unpublished data). Prospective collection of short- and long-
term adverse effects of various surgical procedures is important
as these have likely been underestimated by present studies.
Physiologic characteristics of HH and the nearby hypothal-
amus that might affect surgical outcome were studied, but
the need for an adequate anatomical disconnection of the
HH from the surrounding brain was highlighted. Resting-
state functional MRI studies identify different connectivity
patterns by independent component analysis. These may
identify any HH voxel that is functionally connected to other
non-HH tissue, which is thought to indicate aberrant and
potential pathways for seizure propagation, and correspond
to regions of initial ictal propagation by stereo-EEG; their
targeted ablation may improve seizure outcome.53,54 The
unique electrophysiologic characteristics of both the HH
and the nearby normal hypothalamus were also studied, and
those findings potentially correlated with the area to be
resected/disconnected.55
Figure 2 MRI Examples of Delalande Classification of Hypothalamic Hamartoma (HH)
All panels show coronal T2-weighted MRI. HH lesion type is
designated according to the proposed classification system of
Delalande and Fohlen.44 (A) Type I HH: 2-year-old boy with
mild developmental delay but otherwise asymptomatic. Note
attachment of the HH lesion entirely below the floor of the
third ventricle. (B) Type II HH: 5-year-old boy with a history of
gelastic seizures since 12 months of age. Note attachment to
the left side of the hypothalamus, entirely above the floor of
the third ventricle. (C) Type III HH: 31-year-old woman with
refractory epilepsy, including gelastic seizures since infancy.
Note attachment of the HH lesion to the right side of the hy-
pothalamus both above and below the floor of the third
ventricle. (D) Type IV HH: 3-year-old girl with severe de-
velopmental delay, history of precocious puberty, and multi-
ple daily gelastic seizures. Type IV is designated by Delalande
and Fohlen as a “giant”HH, but criteria to distinguish between
types III and IV were not offered. We (Barrow Neurologic In-
stitute) currently use a volume measurement over 8 cm3 to
designate type IV, measuring themaximal length of the lesion
in the 3major axes, then utilizing the formula for determining
the volume of an ellipsoid (courtesy of John F. Kerrigan, MD,
Barrow Neurologic Institute).
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Ictal surface EEG may deceptively suggest a cortical focus,
which likely represents spread from the HH. Using simulta-
neous stereo-EEG, multiple seizure types were found to
originate in HHwith later spread to cortical regions.56 Seizure
freedom is associated with removal or disconnection of the
HH; cortical resection of presumed epileptogenic areas does
not achieve seizure freedom.
Human HH slices are being used for in vivo modeling in
candidate drug development. One novel therapeutic target is
the cannabinoid receptor 2 (CB2), which has been shown to
be overexpressed in HH. Using this model, CB2 agonists
decreased epileptiform activity and thus may represent a new
potential therapy for HH-associated epilepsy (Wu, un-
published data).
Insights From Other
Encephalopathies
There is precedent for molecular treatment of other epi-
leptic encephalopathies, either in tumors from the same
region or other genetic syndromes that can show im-
provement with pathway-specific targeting. Advances in
molecular genetics allow for precision therapy of other tumors
in the sellar region. For example, there are therapeutic dis-
coveries in low-grade glioma (LGG) with molecular inhibitor
therapy targeting the BRAFV600E mutation.57 LGG can present
as a hypothalamic tumor with a diencephalic syndrome causing
encephalopathy that improves or resolves with tumor treat-
ment. Similarly, there are advances in the molecular target-
ing (everolimus, sirolimus) of the mTOR pathway for the
treatment of tuberous sclerosis. While a study in older
children of mTOR inhibition failed to demonstrate cognitive
improvement,58 some investigators hypothesize that mTOR
inhibition in young children may help prevent or reverse
encephalopathy in tuberous sclerosis complex. Thus, the
expansion of the molecular genetics underlying HH may
provide similar targeted therapies, and the possibility of
improved cognitive outcomes. Such targeted therapies could
include SMO inhibitors like vismodegib that reduce activa-
tion of hedgehog pathway signaling.59 Vismodegib is ap-
proved for clinical use with demonstrated efficacy for lesion
shrinkage or cessation of new lesion development in basal
cell naevus syndrome.e29 Future prospective studies should
incorporate neuropsychological outcomes to formally ad-
dress this issue.
Future Directions
Development of Standardized
Management Guidelines
Care for children with HH is not consistent despite center-
specific expertise. Standardized pre- and postoperative di-
agnostic, treatment (including timing and selection of surgical
approach), and management guidelines for both children and
adults by specialty for neurology, neuropsychology/psychiatry,
endocrinology, and imaging will improve care.
Tissue is important for further characterization of somatic
mutations and to determine cellular origin of HH. It may be
possible to recover HH cells and their DNA from laser abla-
tion probes by adapting a new method developed for stereo-
EEG electrodes.e10 Furthermore, in vivo models may prove
helpful in understanding the pathogenesis of HH. In the ro-
dent models under development, in utero electroporation or
tamoxifen is used to transiently induce expression of somatic
protein truncating GLI3 mutations that are known to cause
HH in humans (West et al., unpublished data).
Another priority is to characterize a cardinal feature of HH
encephalopathy: rage attacks as a distinct feature of HH. A
rating/evaluation scale will be important to create and validate
for further objective assessment. Another area of focus would
be the study of memory dysfunction in HH given the close-
ness of the hypothalamus to local and remote memory
structures (mammillary bodies and more remote memory
circuits, e.g., prefrontal cortex).34 Other topics of interest
include (1) researching the relationship between intellectual
or developmental disability, behavior, and seizure control as
seizure control may not result in improved behavior; (2)
development of pre- and postsurgical psychiatric profiling;
(3) better diagnosis/treatment of ADHD/autism spectrum
disorder in HH; (4) exploring longitudinal study for psychi-
atric comorbidity; (5) evaluating support and intervention for
managing complex behavioral health issues; and (6) directly
comparing the available surgical options.
The question of SUDEP and SUDEP risk needs to be eluci-
dated. Generalized tonic-clonic seizures, a risk factor for
SUDEP, are relatively rare in HH. Thus, HH may provide
insights regarding SUDEP mechanisms given several ana-
tomical projections from the hypothalamus and functional
connection from the HH to the tectum and brainstem
structures were recently implicated in SUDEP models.60
There is also a need for a coordinated, prospective observa-
tional study with standardized assessments and measures to
identify the differential effect of therapies on seizure control,
encephalopathy, and comorbidities including investigation of
early resection/disconnection/ablation on expression of
encephalopathy.
Discussion
HHs are often small, suprasellar masses that can lead to
devastating epileptic encephalopathy and comorbidity. The
past 2 decades have seen advances in the understanding and
management of HH and its comorbidities, with the potential
to prevent or reverse the devastating consequences of this
disease in some patients. HH presents in 2 ways: the intra-
hypothalamic variant presents with pharmacoresistant
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epilepsy (including gelastic seizures), neurocognitive and
behavioral sequelae, and endocrine dysfunction. The para-
hypothalamic variant (seen in syndromic HH such as in
PHS) usually causes central precocious puberty, but these
patients do not develop severe neurologic comorbidities or
epilepsy. The mutations underlying development of syn-
dromic PHS are thought to be inGLI3, whereas only a subset
of the mutations causing nonsyndromic HH are in GLI3,
with variants in other hedgehog and cilia genes still being
discovered. The exact mechanisms underlying the de-
velopment of the severe epilepsy syndrome, encephalopa-
thy, and the neurocognitive/behavioral sequelae (including
rage) remain elusive. Progress is being made with in vitro
and in vivo modeling, molecular genetic analyses, surgical
and ablative therapies, as well as broader studies on the
neurocognitive and behavioral effects of the disease and its
treatment.
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